Primary Hip OsteoarthritisNCT03112785
Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations
A study testing Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA) in people with Primary Hip Osteoarthritis and Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, run by Sahlgrenska University Hospital.
Trial summary
Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects? Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective… Read more about this study
- Who is it for?
- Ages 35 to 75 years
- Conditions the study is for
- Primary Hip Osteoarthritis, Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, Bilateral Hip Disease
- What is being tested?
- Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)
- Type of treatment
- Medical device
- How many people
- 44 participants
- Where
- No sites listed yet
- Study dates
- 17 Mar 2011to Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hip anatomy suitable for the Fitmore stem according to preoperative planning
- Males and females aged 35 to 75 years (with bilateral hip disease).
- Primary osteoarthritis.
- Secondary osteoarthritis due to idiopathic femoral head necrosis, childhood or inflammatory disease. -
Who cannot join
- Treatment with Cortisol or known osteoporosis.
- Low expected activity rate due to other diseases including any generalized joint disease.
- Anatomy unsuitable for the Fitmore stem.
About this study
Official title: Randomized Comparison Between the Fitmore and the CLS Stem in Patients Operated in One-stage Due to Bilateral Symptomatous Hip Disease
Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects?
Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems.
Read more
Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction.
Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity).
Number of hips in the study: 44 consecutive cases
Read the detailed description
Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects?
Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems.
Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction.
Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity).
Number of hips in the study: 44 consecutive cases
Methods: EQ-5D including VAS-scale to evaluate pain and over all satisfaction, (specific questionnaire concerning side preference), Harris Hip Score, DXA, radiostereometry and gait analysis.
- Clinical parameters: EQ-5D form (including VAS for pain and satisfaction) is filled in by the patients. Harris Hip Score is filled in by the examiner. SF-36 and activity scale (UCLA) is filled in by the patient. Patients also fill in a study specific form including questions about hip preferred and a pain drawing. Clinical parameters will be studied preoperative after 1, 2, 5, 7 and 10 years.
- Conventional radiography: Examinations will be done preoperatively, postoperatively, after 1, 2, 5, 7 and 10 years.
- Computed tomography: Preoperatively, after 1 and 7 years.
- DXA measurements: Postoperatively, after 6 months, 1, 2, 5, 7 and 10 years.
- Radiostereometry: Postoperatively, after 3 and 6 months, 1, 2, 5, 7 and 10 years.
- Gait analysis: 1 and 2 years.
Focus of interest:
- Patient reported outcomes and especially Oxford Hip Score will constitute our primary outcome parameter.
- Conventional radiography (preop with metallic indicator to determine magnification) will include AP, True lateral and pelvic view.
- Computed Tomography will be done for preoperative planning in 3D (a new software has been developed). Preoperative planning in 3D will be done for booth types of prostheses. A prerequisite is that we have 3D-models available for all implants used in the study. Preoperative planning will also be done in 2D.
The CT-examinations will be also used to measure the anteversion of the femur (preoperatively) and of the femoral component (1 year exam). The influence of this parameter on clinical results and fixation will be studied. CT at 7 years will be compared with previous examinations to study development of any osteolysis.
- DXA - studies will be done to study bone remodelling in terms of changes of bone mineral density around the implant. Both the femoral- and the acetabular side will be studied.
- Radiostereometry. The cup will be marked during surgery. Model based RSA for the cup Component will also be used. On the femoral side the femoral head centre will be used to measure stem migration. Tantalum markers will be inserted into the acetabular bone and proximal femur.
Femoral component migration will be measured as translations of the femoral head centre in three directions (medial/lateral, proximal/distal, anterior/posterior). Implant migration between the 6 months and 1 year follow up will constitute our second outcome parameter.
Comments: From previous studies of uncemented stems it has been found that these implants often subside up to 1-2 mm and some even more during 6 months (rarely up to 1 year) and may thereafter become stable and at least according to conventional radiography achieve osseous fixation.
Two years after the operation patients will also be studied using dynamic RSA during active abduction and flexion. The aim is to study any-lift off during these motions. A new radiostereometric laboratory has been installed in 2010 which has facilitated these types of examinations.
In addition the fixation of the cup and wear (femoral head penetration) will be measured.
- Gait analysis will be performed one and two years after the operation. The patients will be studied walking and when rising from a chair. This analysis will focus on flexion/extension, motions of the hip and the knee and the ground reacting forces. The ab/adduction movements over the hip during walking will also be recorded.
- Conditions
- Primary Hip Osteoarthritis, Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, Bilateral Hip Disease, Surgical Treatment
- Being tested
- Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)
- Keywords
- Hip, Arthroplasty, Stem, Outcome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)Device
The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
What is being measured
The primary outcome is the main question the study is designed to answer.
Preferred hip (the hip arthroplasty preferred by the patient, right or left side)
Study specific protocol in which the patient from a general view tics one of 3 options: left side, right side or no difference). In the term preferred view the patient is asked to consider all aspects they Think are important such as freedom from pain, mobility, function or any other type of discomfort.
Measured: 2 years
Secondary outcomes (3)
Stem subsidence (distal migration of the stem)
Stem subsidence in mm (distal migration of the femoral head center) measured with radiostereometry
Measured: 2 years
Extent of radiolucent lines around the stem
Development of radiolucent lines in percent of total stem circumference as measured on conventional radiographs
Measured: 2 years
Any new surgical procedure where the stem is removed or Exchanges (revision of the stem)
Stem Exchange or removal due to loosening, dislocation or periprostheic fracture
Measured: 2, 5 and 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2017
- Study start17 Mar 2011
- Primary completionJun 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Hip OsteoarthritisStudies of the same condition, open and under way.
- More trials run by Sahlgrenska University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients with bilateral degenerative hip osteoarthritis are operated with a short stem total hip arthroplasty on one side and a conventional stem on the opposite side. Implant selection is randomised on the most symptomatic side, the second side receives the type of stem not used on the first one.
- Masking
- None (open label)
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sahlgrenska University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Zimmer Biomet
- Responsible party
- Principal investigator, Johan Karrholm, Sahlgrenska University Hospital
- Investigators
- Johan N Kärrholm, MD, Professor, Principal investigator, Sahlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03112785
- Sponsor's protocol ID
- Fitmore2011
- Status last verified
- Apr 2017
- First submitted
- 7 Mar 2017
- Last updated
- 13 Apr 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Comparison Between the Fitmore and the CLS Stem in Patients Operated in One-stage Due to Bilateral Symptomatous Hip Disease
- ClinicalTrials.gov ID
- NCT03112785
- Acronym / sponsor ID
- Fitmore2011
- Conditions
- Primary Hip Osteoarthritis, Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, Bilateral Hip Disease, Surgical Treatment
- Keywords
- Hip, Arthroplasty, Stem, Outcome
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Sahlgrenska University HospitalUniversity, hospital or other
- Collaborators
- Zimmer Biomet
- Study start
- 17 Mar 2011 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 13 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects?
Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems.
Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction.
Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity).
Number of hips in the study: 44 consecutive cases
Detailed description
Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects?
Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems.
Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction.
Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity).
Number of hips in the study: 44 consecutive cases
Methods: EQ-5D including VAS-scale to evaluate pain and over all satisfaction, (specific questionnaire concerning side preference), Harris Hip Score, DXA, radiostereometry and gait analysis.
- Clinical parameters: EQ-5D form (including VAS for pain and satisfaction) is filled in by the patients. Harris Hip Score is filled in by the examiner. SF-36 and activity scale (UCLA) is filled in by the patient. Patients also fill in a study specific form including questions about hip preferred and a pain drawing. Clinical parameters will be studied preoperative after 1, 2, 5, 7 and 10 years.
- Conventional radiography: Examinations will be done preoperatively, postoperatively, after 1, 2, 5, 7 and 10 years.
- Computed tomography: Preoperatively, after 1 and 7 years.
- DXA measurements: Postoperatively, after 6 months, 1, 2, 5, 7 and 10 years.
- Radiostereometry: Postoperatively, after 3 and 6 months, 1, 2, 5, 7 and 10 years.
- Gait analysis: 1 and 2 years.
Focus of interest:
- Patient reported outcomes and especially Oxford Hip Score will constitute our primary outcome parameter.
- Conventional radiography (preop with metallic indicator to determine magnification) will include AP, True lateral and pelvic view.
- Computed Tomography will be done for preoperative planning in 3D (a new software has been developed). Preoperative planning in 3D will be done for booth types of prostheses. A prerequisite is that we have 3D-models available for all implants used in the study. Preoperative planning will also be done in 2D.
The CT-examinations will be also used to measure the anteversion of the femur (preoperatively) and of the femoral component (1 year exam). The influence of this parameter on clinical results and fixation will be studied. CT at 7 years will be compared with previous examinations to study development of any osteolysis.
- DXA - studies will be done to study bone remodelling in terms of changes of bone mineral density around the implant. Both the femoral- and the acetabular side will be studied.
- Radiostereometry. The cup will be marked during surgery. Model based RSA for the cup Component will also be used. On the femoral side the femoral head centre will be used to measure stem migration. Tantalum markers will be inserted into the acetabular bone and proximal femur.
Femoral component migration will be measured as translations of the femoral head centre in three directions (medial/lateral, proximal/distal, anterior/posterior). Implant migration between the 6 months and 1 year follow up will constitute our second outcome parameter.
Comments: From previous studies of uncemented stems it has been found that these implants often subside up to 1-2 mm and some even more during 6 months (rarely up to 1 year) and may thereafter become stable and at least according to conventional radiography achieve osseous fixation.
Two years after the operation patients will also be studied using dynamic RSA during active abduction and flexion. The aim is to study any-lift off during these motions. A new radiostereometric laboratory has been installed in 2010 which has facilitated these types of examinations.
In addition the fixation of the cup and wear (femoral head penetration) will be measured.
- Gait analysis will be performed one and two years after the operation. The patients will be studied walking and when rising from a chair. This analysis will focus on flexion/extension, motions of the hip and the knee and the ground reacting forces. The ab/adduction movements over the hip during walking will also be recorded.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Model description
- Patients with bilateral degenerative hip osteoarthritis are operated with a short stem total hip arthroplasty on one side and a conventional stem on the opposite side. Implant selection is randomised on the most symptomatic side, the second side receives the type of stem not used on the first one.
Who may qualify
- Ages
- 35 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Hip anatomy suitable for the Fitmore stem according to preoperative planning
- Males and females aged 35 to 75 years (with bilateral hip disease).
- Primary osteoarthritis.
- Secondary osteoarthritis due to idiopathic femoral head necrosis, childhood or inflammatory disease. -
Key exclusion criteria (3 listed)
- Treatment with Cortisol or known osteoporosis.
- Low expected activity rate due to other diseases including any generalized joint disease.
- Anatomy unsuitable for the Fitmore stem.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup. | Device | – |
Primary outcome
Preferred hip (the hip arthroplasty preferred by the patient, right or left side)
Time frame: 2 years
Study specific protocol in which the patient from a general view tics one of 3 options: left side, right side or no difference). In the term preferred view the patient is asked to consider all aspects they Think are important such as freedom from pain, mobility, function or any other type of discomfort.
3 secondary outcomes
Stem subsidence (distal migration of the stem)
Time frame: 2 years
Extent of radiolucent lines around the stem
Time frame: 2 years
Any new surgical procedure where the stem is removed or Exchanges (revision of the stem)
Time frame: 2, 5 and 10 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2017.
- Individual participant dataSharing planned: No
Related trials for Primary Hip Osteoarthritis
Not yet recruiting
DEXA Bone Density Analysis of the CoreHip® Prosthesis System
Primary Osteoarthritis, Cartilage Degeneration
Active, not recruitingObservational study
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay
Primary Osteoarthritis, Secondary Osteoarthritis
Recruiting
Hip Replacement System (HRS-P) in Primary Total Hip Arthroplasty
Osteoarthritis of Hip
Recruiting
Safety and Effectiveness of the HIT Reverse HRS
Degenerative Joint Disease, Osteoarthritis, Hip
Recruiting
Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem
Osteoarthritis, Hip, Femur Head Necrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johan N Kärrholm, MD, Professor principal investigator
Sahlgrenska University Hospital
Questions about this trial
What is this clinical trial studying?
A study testing Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA) in people with Primary Hip Osteoarthritis and Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, run by Sahlgrenska University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Preferred hip (the hip arthroplasty preferred by the patient, right or left side) (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2017.